Hot Features
Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases.
- Pivotal Phase 3 LUCIDITY trial will evaluate FDA-agreed upon primary outcome of reduction in hypoglycemia events and designed to align as closely as possible with previous Phase 2 trial designs...
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that management will participate in the 7th Annual Evercore ISI HealthCONx Conference. The conference is...
On track to initiate a Phase 3 program for Company’s lead asset avexitide, a GLP-1 receptor antagonist with FDA Breakthrough Therapy and Orphan Drug Designations, in post-bariatric hypoglycemia...
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) will report its third quarter 2024 financial results on Thursday, November 7, 2024. Amylyx’ senior management team will...
- Improvement observed in pancreatic function, as measured by C-peptide response, following 24 weeks of treatment with AMX0035; worsening is typically expected with disease progression based on...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.35 | -8.55745721271 | 4.09 | 4.15 | 3.73 | 533503 | 3.9392723 | CS |
| 4 | -1.725 | -31.5645013724 | 5.465 | 5.51 | 3.73 | 743983 | 4.36134863 | CS |
| 12 | 0.66 | 21.4285714286 | 3.08 | 7.27 | 3.08 | 1301975 | 4.95547705 | CS |
| 26 | 1.86 | 98.9361702128 | 1.88 | 7.27 | 1.62 | 1334555 | 3.49010144 | CS |
| 52 | -10.98 | -74.5923913043 | 14.72 | 19.9488 | 1.575 | 1878846 | 4.69367148 | CS |
| 156 | -17.26 | -82.1904761905 | 21 | 41.9297 | 1.575 | 1341707 | 14.63799885 | CS |
| 260 | -17.26 | -82.1904761905 | 21 | 41.9297 | 1.575 | 1341707 | 14.63799885 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
